Cyclopharm (CYC) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASX
KalkineWhy Is Cyclopharm (ASX:CYC) Stirring Smallcaps?
Highlights Cyclopharm is drawing attention as fresh medical imaging guidance lifting attention to smaller healthcare names. Today's ASX tone is shaped by smallcap healthcare is rewarding evidence over broad promises. The key question is can specialist healthcare names earn attention while the wider sector is fragile. A: ustralia's sharemarket has opened with a firmer pulse, and AFT Pharmaceuticals (ASX:AFP), a regional pharmaceutical company with product development programs, is helping frame...
Why Is Cyclopharm (ASX:CYC) in Health Focus?
Highlights Cyclopharm is drawing attention as Technegas recognition in updated lung imaging guidance. Today's ASX tone is shaped by specialist healthcare names can move when evidence becomes clearer. The key question is whether guideline recognition can support a broader commercial conversation. A: ustralia's sharemarket has opened with a firmer pulse, and AFT Pharmaceuticals (ASX:AFP), a regional pharmaceutical company with product development programs, is helping frame why Cyclopharm matter...
Google NewsCyclopharm (ASX:CYC) named preferred agent in first US lung imaging rewrite in 14 years - Stocks Down Under
Cyclopharm (ASX:CYC) named preferred agent in first US lung imaging rewrite in 14 years Stocks Down Under
New US Lung Imaging Guidelines Name Technegas as Preferred A
other announcement
Cyclopharm Ltd (ASX:CYC) Jumps 25.77% as Shares Reach AUD 0.61 - Kalkine
Cyclopharm Ltd (ASX:CYC) Jumps 25.77% as Shares Reach AUD 0.61 Kalkine
Small CapsImmediate 11-Site Technegas Rollout at University Hospitals
other announcement
Appointment of Non-Executive Director and Incoming Chair
other announcement
Resignation of Non-Executive Director John Wigglesworth
other announcement
CYC Secures Multi-Site Agreement with Northwestern Medicine
other announcement
Change of Director's Interest Notice - JM
director_dealing announcement
Change of Director's Interest Notice - KB
director_dealing announcement
Change of Director's Interest Notice - JW
director_dealing announcement
Change of Director's Interest Notice - DA
director_dealing announcement
Change of Director's Interest Notice - DH
director_dealing announcement
Technegas US Footprint Expanding Across Four Regions
other announcement
Technegas Approved at the US National Institutes of Health
other announcement
Cyclopharm Successfully Completes A$14 million Placement
capital_raise announcement
Cyclopharm Capital Raising Investor Presentation
other announcement
CYC Unaudited Trading Update - Preliminary FY2025 Results
other announcement
COPD Study Leveraging Technegas and AI-Driven Lung Analysis
other announcement
Technegas Recognised in Updated Clinical Guideline
other announcement